Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
157
resultados
Última actualización
25/09/2025 [07:42:00]
Resultados 25 a 50 de 157
Resumen de: US2025281466A1
New treatments using Clopidogrel, Ticagrelor, Prasugrel, and/or Cangrelor and new uses for Clopidogrel are disclosed herein. For example, it has been found that conditions such as ALS (Amyotrophic Lateral Sclerosis), Alzheimer's Disease, the normal aging process, nerve damages, nerve injuries, muscular dystrophy, strenuous physical activities, fatigue, and other conditions that affect synapses as well as skeletal muscles can be treated using Clopidogrel or pharmaceutically acceptable other forms. New mechanisms and modes of action are explained herein.
Resumen de: US2025281500A1
Compositions and methods for treating Huntington's disease with a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in combination with pridopidine, or a pharmaceutical salt thereof, are provided. The compositions and methods may be used to improve one or more symptoms of Huntington's disease.Formula (I):or pharmaceutically acceptable salts thereof, wherein R1, R2, R7 and ring A have any of the meanings herein defined in the description.
Resumen de: US2025282852A1
Provided herein are methods of promoting removal of beta-amyloid (Aβ) plaque, methods of reducing neuroinflammation, and methods treating a neurological disorder (e.g., Alzheimer's Disease) with certain bispecific antibodies or antigen-binding fragments with one specificity against an internalizing antigen expressed on the surface of neurological cells and the other specificity against a toxic form of Aβ protein. Exemplary antibodies, characteristics thereof, and methods of screening for additional therapeutic bispecific antibodies are also described herein.
Resumen de: US2025282838A1
The disclosure provides peptide compositions and immunotherapy compositions comprising an amyloid-beta (Aβ) peptide and a tau peptide. The disclosure also provides methods of treating or effecting prophylaxis of Alzheimer's disease or other diseases with beta-amyloid deposition in a subject, including methods of clearing deposits, inhibiting or reducing aggregation of Aβ and/or tau, blocking the uptake by neurons, clearing amyloid, and inhibiting propagation of tau seeds in a subject having or at risk of developing Alzheimer's disease or other diseases containing tau and/or amyloid-beta accumulations. The methods include administering to such patients the compositions comprising an amyloid-beta (Aβ) peptide and a tau peptide.
Resumen de: US2025282725A1
Small molecule potentiatiors to potassium channels (such as Kv7 potentiators—which are also called KCNQ potentiators), compositions including such compounds, and methods of using such compounds for the treatment of Amyotrophic Lateral Sclerosis and other neurological diseases caused by changes in motor neuron excitability, including, but not limited to, primary lateral sclerosis, pseudobulbar palsy, progressive bulbar palsy, progressive muscular atrophy and epilepsy.
Resumen de: US2025282724A1
The present invention aims to provide a medicament capable of treating and/or preventing diseases associated with oxidative stress by inhibiting the protein-protein interaction between Keap1 and Nrf2 and activating Nrf2. The present invention relates to a compound represented by the following formula (1):wherein each symbol is as described in the DESCRIPTION, or a pharmaceutically acceptable salt thereof. In addition, the present invention also relates to a medicament containing the aforementioned compound, for the prophylaxis and/or treatment of diseases involving oxidative stress selected from the group consisting of chronic kidney disease, non-alcoholic steatohepatitis, chronic obstructive pulmonary disease, radiation skin disorder, radiation mucosal disorder, cardiac failure, pulmonary arterial hypertension, Parkinson's disease, Friedreich's ataxia, multiple sclerosis, age-related macular degeneration, retinitis pigmentosa and glaucoma.
Resumen de: US2025283075A1
The present disclosure provides methods for treating inflammatory disease, such as Alzheimer's disease, by administering an inhibitor of Fli-1, such as an antisense oligonucleotide. Further provided are antisense gapmer oligonucleotides for targeting Fli-1.
Resumen de: US2025283074A1
Provided are methods for treating Alzheimer's Disease and/or ameliorating at least one symptom thereof. In some embodiments, the methods include administering to a. subject with AD an inhibitor of a clusterin biological activity, wherein the composition is administered via a route and in an amount sufficient to inhibit the clusterin biological activity to thereby treat the subject's. AD and/or ameliorate at least one symptom thereof. Also provided are methods for reducing and/or inhibiting myelin decay in a subject in need thereof and methods for inhibiting differentiation of oligodendrocyte progenitor cells (OPCs) to mature oligodendrocytes, the method comprising contacting the OPCs with a clusterin gene product or a functional fragment or derivative thereof.
Resumen de: AU2024222862A1
The invention provides berberine tauroursodeoxycholate (BTUDC), pharmaceutical compositions and methods of use thereof for the treatment, reduction and/or prevention of Parkinson's disease, or an associated disease and disorder, as monotherapy or in combination with other agents or as an adjuvant. The invention further provides pharmaceutical compositions and methods of use of berberine (BBR) and tauroursodeoxycholic acid (TUDCA) for the treatment, reduction and/or prevention of Parkinson's disease, or an associated disease and disorder, as monotherapy or in combination with other agents or as an adjuvant.
Resumen de: US2025281488A1
The present invention relates to inhibitors of Valosin-containing protein (VCP or p97) and the use thereof in the treatment or prevention of diseases such as amyotrophic lateral sclerosis (ALS). In particular the present invention provides VCP inhibitors for use in a method of treating or preventing ALS wherein the subject has been identified as not having a disease-causing genetic mutation in a VCP gene (non-VCP-associated ALS). The invention also relates to methods of identifying a patient as not having a disease-causing mutation in a VCP gene.
Resumen de: EP4613281A1
The present invention relates to a composition for preventing, ameliorating, or treating Alzheimer's disease comprising grapevine stem extract or a compound isolated therefrom as an effective component. Specifically, as the grapevine stem extract and vitisin A as an effective component of the present invention exhibit an excellent effect of inhibiting infection with the herpes simplex virus and inhibiting Alzheimer-causing factors in the brain tissue of animal models infected with the herpes simplex virus, the composition of the present invention can be advantageously used as an agent for treating Alzheimer's disease or a functional health food or an animal feed additive for preventing or ameliorating Alzheimer's disease.
Resumen de: EP4613277A1
The present invention relates to a composition for preventing, ameliorating or treating cognitive dysfunction or Alzheimer's disease comprising, as an active ingredient, Lactobacillus fermentum SRK414 strain which has accession number KCTC13687BP. The strain of the present invention is excellent in reducing barrier permeability and reducing amyloid beta and tau proteins and has an excellent effect in improving cognitive function, and accordingly, the strain can be useful for a food and therapeutic agent for same purposes.
Resumen de: EP4613278A1
The present invention relates to a composition for preventing, alleviating or treating cognitive impairment or Alzheimer's disease, comprising a Lactobacillus delbrueckii subsp. lactis strain as an active ingredient. The present invention provides a composition for preventing, alleviating or treating cognitive impairment or Alzheimer's disease (AD), comprising a Lactobacillus delbrueckii subsp. lactis strain as an active ingredient. The strain of the present invention has the excellent effects of reducing amyloid beta protein (Aβ) or tau protein (Tau) and improving cognitive function, and thus can be effectively used as a composition for preventing, alleviating or treating cognitive impairment or AD.
Resumen de: WO2024097164A1
Provided are methods of phosho-tau aggregation-based biomarker discovery, and new utilities for discovered biomarkers in Alzheimer's disease (AD) diagnosis, differentiation, and treatment. Novel p-tau sites, p-tau198, p-tau396, and p-tau422, identified through such methods showed comparable or superior characteristics with established p-tau biomarkers, and identified biomarkers were capable of differentiating AD or mild cognitive impairment (MCI) from cognitively normal controls.
Resumen de: US2025276011A1
The present disclosure provides, among other things, methods for the treatment of neurodegenerative diseases (ND) and other mitochondrial disorders, and compositions related thereto. Described herein are in vitro (cell culture) and in vivo (animal model) experimental examples demonstrating mitochondrial organelle transplantation (MOT) for the treatment of NDs such as amyotrophic lateral sclerosis (ALS). Furthermore, as discussed herein, MOT has been performed in five human ALS patients with positive results—measurable improvement of their conditions has been observed, with no adverse events.
Resumen de: US2025275936A1
Compositions and methods for treating a cancer or a neurological disease. A method of treating a cancer or a neurological disease comprising administering to a subject in need thereof an effective amount of quercetin, vitamin B3, vitamin C, folic acid, a chemotherapeutic agent, and zafirlukast. A method of treating amyotrophic lateral sclerosis comprising administering to a subject in need thereof an effective amount of quercetin, vitamin B3, vitamin C, folic acid, a chemotherapeutic agent, and zafirlukast.
Resumen de: US2025275935A1
Compositions and products (e.g., kits, medical devices, medicaments), which incorporate the compositions, comprising a tetrahydrocannabinol (THC) compound and melatonin compound are provided, Methods for treatment using the compositions and products, methods for diagnosis before or after treatment, and processes for formulating the compositions or manufacturing the products are also provided. They address the need for new treatments of cognitive and perceptual deficits, neuropsychiatric symptoms, neurodegenerative diseases, and neurologic disorders. The inventors discovered therapeutically effective amounts of TI-IC and melatonin can be administered to treat patients, without need for an entourage effect or requirement of cannabidiol (CBD) and other cannabinoid compounds. Optionally, polyphenolic compounds (e.g., curcumin-related compounds, rutin-related compounds) and/or Vitamin E-related compounds (e.g., mixed tocopherols, alpha-tocopherol, beta-tocopherol, gamma-tocopherol) may be administered together with or separately from TI-IC and melatonin compounds.
Resumen de: US2025275953A1
The present disclosure relates to a method of treating, or delaying, inhibiting, or suppressing of the progression of, a neurodegenerative disease such as, for example, early-stage Parkinson's disease comprising administering a c-Abl inhibitor (such as vodobatinib, or a pharmaceutically acceptable salt thereof) to a subject in need thereof.
Resumen de: US2025277203A1
The invention relates to expression vectors, and pharmaceutical compositions, and kits comprising the vectors, and, in particular, their use in methods for treating Parkinson's disease (PD), DOPA responsive dystonia, vascular parkinsonism, side effects associated with L-DOPA treatment for Parkinson's disease, L-DOPA induced dyskinesia, Segawa syndrome, or genetic dopamine receptor abnormalities.
Resumen de: US2025277040A1
The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful in correcting a deficient level of progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).
Resumen de: WO2025184593A1
The present disclosure provides methods for preventing or treating a neurodegenerative disorder in a subject, where the neurodegenerative disorder is one characterized by a deposition of abnormal tau protein in the brain of the subject. The method generally includes administering to the subject a therapeutically effective amount of a drug that is a tau propagation antagonist.
Resumen de: WO2025184490A1
The present disclosure provides methods of treating Alzheimer's Disease (AD) using Compound (I) as represented by the structure below: Formula should be inserted here or a free base or pharmaceutically acceptable salt thereof.
Resumen de: WO2025184649A1
The present disclosure provides methods related to treating neurodegeneration and neuroinflammation. In particular, the present disclosure identifies YTH domain-containing family protein 1 (YTHDF1) as a novel therapeutic target for Alzheimer's disease. Embodiments of the present disclosure provide methods of therapy for neurodegenerative disease that involve inhibiting YTHDF1 to induce attenuation of chronic neuroinflammation.
Resumen de: AU2025213702A1
Abstract Provided herein are cannabinoid-containing complex mixtures suitable for use as active pharmaceutical ingredients. The complex mixtures comprise at least a first major cannabinoid, at least a first minor cannabinoid, and optionally at least a first selected terpene. Also provided are methods of making the complex mixtures; pharmaceutical compositions comprising the complex mixture, and methods of using the pharmaceutical compositions for the treatment of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, Lewy Body Dementia, or Huntington's disease. Abstract Provided herein are cannabinoid-containing complex mixtures suitable for use as active pharmaceutical ingredients. The complex mixtures comprise at least a first major cannabinoid, at least a first minor cannabinoid, and optionally at least a first selected terpene. Also provided are methods of making the complex mixtures; pharmaceutical compositions comprising the complex mixture, and methods of using the pharmaceutical compositions for the treatment of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, Lewy Body Dementia, or Huntington's disease.
Nº publicación: WO2025181155A1 04/09/2025
Solicitante:
VIB VZW [BE]
VRIJE UNIV BRUSSEL [BE]
UNIV DEGLI STUDI DI PADOVA [IT]
VIB VZW,
VRIJE UNIVERSITEIT BRUSSEL,
UNIVERSIT\u00C0 DEGLI STUDI DI PADOVA
Resumen de: WO2025181155A1
This application relates to polypeptide agents and compositions specifically binding human beta-glucocerebrosidase (GCase, GBA1). Particularly, immunoglobulin single variable domains (ISVDs) are described which allosterically bind human GCase, thereby positively modulating GCase in its stability and/or catalytic activity. The invention relates further to vectors and nucleic acids encoding such ISVD-based modulators. Also encompassed are compositions, in particular pharmaceutical compositions, containing such ISVD modulators. The GCase-specific allosteric modulators, specifically the ISVDs and compositions described herein, may be used for prevention and/or treatment of GCase-related diseases, including Gaucher disease (GD) and Parkinson's disease (PD).
BOPI
Sede Electrónica
